RNA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.0%, SMA50 0.42%, SMA200 38.79%). The stock’s 14-day RSI is 57.58 (neutral), while the ATR of 0.22 points to moderate volatility. The stock remains hovering near 52-week lows, trading -0.36% below its high and over 238.45% above its low. Average 10-day trading volume of 209.35 thousand shares is below the 3-month average of 1.51 million, indicating normal recent market interest.

Atrium Therapeutics, Inc. has 128.65 million shares outstanding. The public float is 98.07 million shares, elevated short interest at 12.71% of float. This equals 16.21 million shares. The short ratio is 6.27 days. Institutional investors hold 19.75% of the float. Insiders own 2.79%. RTW INVESTMENTS, LP holds 4.80 million shares, Cormorant Asset Management, LP has 2.51 million shares and Boyce Sarah has 269.01 thousand shares. Over the past six months, insider transactions show net selling. They sold 42.74 thousand shares across 13 transactions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Atrium Therapeutics, Inc. (NASDAQ:RNA) closed at $12.87 USD, losing -$0.56 (-4.17%) from the previous close of $13.43. The stock is currently mid-range between its 52-week high and low $11.95 and $16.77. With a market capitalization of about $199.68 million, Atrium Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 874.39 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Atrium Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kathleen Gallagher, the company employs approximately 511 people and listed since February 27, 2026. Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.

Atrium Therapeutics, Inc. generated EPS of -$4.96 over the past year. Five-year average earnings growth is -19.41%. Wall Street analysts project EPS growth of -11.51% annually over the next five years. The latest quarter delivered EPS of -$1.70. The next quarter is forecast at -$1.32. Next year's EPS is expected at -$28.91. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 8 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $96.00 to $25.00. The high target offers 645.92% upside. The low target suggests 94.25% downside. The mean target is $67.78. This offers 426.65% upside. Atrium Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 02, 2026, missed forecasts by 37.1%. The prior quarter beat by -50.81%. Over the last six quarters, Apple has recorded several small beats. These include 5.26% in February 27, 2025.

Atrium Therapeutics, Inc. (NASDAQ:RNA) shares are flat 0.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Atrium Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.88. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $57.94, suggesting 350.19% upside. Our AI forecast model points to short-term weakness (-1.01% over two weeks), a medium-term fall (-27.97% over three months), and a longer-term loss (-92.85% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Atrium Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.01%, with price expected at $12.74 by May 18, 2026, within a range of $11.96 to $13.43 3-Month Outlook: Projected fall of -27.97%, reaching $9.27 by July 31, 2026, with a range of $6.25 to $11.67. 1-Year Outlook: Projected loss of -92.85%, with price at $0.92 by May 04, 2027, within a range of $0.00 to $0.00.

Atrium Therapeutics, Inc. trades at a P/E ratio of -2.88, slightly below the S&P 500 average, with a price-to-sales ratio of 10.77 and a price-to-book ratio of 1.07 suggesting the stock is closer to book value. The P/FCF stands at -4.71, also above market averages.